Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 20;27(5):383-390.
doi: 10.3779/j.issn.1009-3419.2024.106.11.

[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer]

[Article in Chinese]
Peng Song  1 , Yong Cui  1
Affiliations
Review

[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer]

[Article in Chinese]
Peng Song et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis. Recently, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC, and are recommended by the guidelines for clinical use. In this review, we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC, and discuss the key issues in the clinical researches. .

【中文题目：EGFR突变可切除的NSCLC围手术期 辅助靶向治疗研究进展及问题探讨】 【中文摘要：肺癌在全球范围内仍是导致癌症死亡的首要原因，非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌的主要病理类型，占80%左右。在所有NSCLC患者中，约30%初诊时为可切除的早中期NSCLC。近期表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs）在EGFR突变可切除的NSCLC围手术期辅助靶向治疗中取得重大突破，并被指南推荐应用于临床。本文在总结EGFR突变可切除NSCLC围手术期辅助靶向治疗临床研究进展的基础上，针对临床研究中的关键问题进行探讨。 】 【中文关键词：肺肿瘤；围手术期治疗；新辅助治疗；辅助治疗；靶向治疗】.

Keywords: Adjuvant treatment; Lung neoplasms; Neoadjuvant treatment; Perioperative treatment; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Goldstraw P, Chansky K, Crowley J, et al.. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol, 2016, 11(1): 39-51. doi: 10.1016/j.jtho.2015.09.009 - DOI - PubMed
    1. Paez JG, Janne PA, Lee JC, et al.. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science, 2004, 304(5676): 1497-1500. doi: 10.1126/science.1099314 - DOI - PubMed
    1. Li WZ, Cai YG. Application status and progress of EGFR-TKI in the treatment of EGFR-mutant non-small cell lung cancer. Linchuang Yixue Yanjiu Yu Shijian, 2022, 7(7): 187-191.
    2. [李旺珍, 蔡永广. EGFR-TKI在EGFR突变非小细胞肺癌治疗中的应用现状及进展. 临床医学研究与实践, 2022, 7(7): 187-191.] doi: 10.19347/j.cnki.2096-1413.202207055 - DOI
    1. Wu YL, Lee JS, Thongprasert S, et al.. Intercalated combination of chemotherapy and Erlotinib for patients with advanced stage non-small cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol, 2013, 14(8): 777-786. doi: 10.1016/S1470-2045(13)70254-7 - DOI - PubMed
    1. Mitsudomi T, Morita S, Yatabe Y, et al.. Gefitinib versus Cisplatin plus Docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128. doi: 10.1016/S1470-2045(09)70364-X - DOI - PubMed

MeSH terms